1
|
Ruppen I, Verscheure L, Vandenheede I, Ortiz A, de Melo IS, Liebig T, Sandra P, Beydon ME, Sandra K. Characterization of mAb size heterogeneity originating from a cysteine to tyrosine substitution using denaturing and native LC-MS. J Pharm Biomed Anal 2023; 236:115743. [PMID: 37757547 DOI: 10.1016/j.jpba.2023.115743] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2023] [Revised: 09/19/2023] [Accepted: 09/20/2023] [Indexed: 09/29/2023]
Abstract
Upon assessing the comparability between a biosimilar mAb and its reference product by non-reducing CE-SDS, increased levels of a heavy-heavy-light chain (HHL) variant, present as a low molecular weight (LMW) peak, were observed. RPLC-MS applied at top, middle-up and bottom-up level revealed the existence of Cys-to-Tyr substitutions, predominantly at position HC226 involved in connecting LC and HC, explaining the abundant HHL levels. Antigen binding was not impacted by the presence of this size variant suggesting a non-covalent association of Tyr substituted HHL and LC. The latter complex is not maintained in the denaturing conditions associated with CE-SDS and RPLC-MS. Its existence could, nevertheless, be confirmed by native SEC-MS which preserves non-covalent protein interactions during separation and electrospray ionization. Amino acid analysis furthermore demonstrated a depletion of Cys during the fed-batch process indicating that the observed size/sequence variant is not of genetic but rather of metabolic origin. Native SEC-MS showed that supplementing the cell culture medium with Cys halts misincorporation of Tyr and promotes the formation of the desired mAb structure. To the best of our knowledge, Cys-to-Tyr substitutions preventing interchain disulfide bridge formation have not been described earlier. This observation adds to the impressive structural heterogeneity reported to date for mAbs.
Collapse
Affiliation(s)
- Isabel Ruppen
- mAbxience Research, Manuel Pombo Angulo 28, 28050 Madrid, Spain
| | | | | | - Alexia Ortiz
- RIC group, President Kennedypark 26, 8500 Kortrijk, Belgium
| | | | - Timo Liebig
- mAbxience Research, Manuel Pombo Angulo 28, 28050 Madrid, Spain
| | - Pat Sandra
- RIC group, President Kennedypark 26, 8500 Kortrijk, Belgium
| | | | - Koen Sandra
- RIC group, President Kennedypark 26, 8500 Kortrijk, Belgium.
| |
Collapse
|
2
|
Niu B, Lu Y, Chen X, Xu W. Using New Peak Detection to Solve Sequence Variants Analysis Challenges in Bioprocess Development. JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY 2023; 34:401-408. [PMID: 36705517 DOI: 10.1021/jasms.2c00292] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/18/2023]
Abstract
Recombinant therapeutic proteins have become the major class of drugs to treat various human diseases in recent years. Low levels of protein sequence variants (SVs) have been reported to be present in recombinant therapeutic proteins. The consequences of potential unwanted immune response from SVs of recombinant therapeutic proteins have increasingly drawn attention from regulatory authorities and the biopharmaceutical industry. It is highly desirable to detect low-level SVs during clone selection and early process development as part of the control strategy. Peptide mapping with LC-MS/MS analysis has been applied as a powerful tool to characterize post-translation modifications of therapeutic proteins. Despite the recent advancements in mass spectrometry hardware and software, it is still quite challenging and time-consuming to detect and identify low-level SVs. In this study, we present an optimized approach using new peak detection to detect and identify low level SVs with high confidence and high speed. The new approach makes sequence variants analysis by LC-MS/MS broadly applicable and practical in bioprocess development of therapeutic proteins.
Collapse
Affiliation(s)
- Ben Niu
- Analytical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland20878United States
| | - Yali Lu
- Analytical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland20878United States
| | - Xiaoyu Chen
- Analytical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland20878United States
| | - Wei Xu
- Analytical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland20878United States
| |
Collapse
|
3
|
Kelsall E, Harris C, Sen T, Hatton D, Dunn S, Gibson S. Interplay of heavy chain introns influences efficient transcript splicing and affects product quality of recombinant biotherapeutic antibodies from CHO cells. MAbs 2023; 15:2242548. [PMID: 37555672 PMCID: PMC10413919 DOI: 10.1080/19420862.2023.2242548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2023] [Revised: 07/12/2023] [Accepted: 07/26/2023] [Indexed: 08/10/2023] Open
Abstract
Introns are included in genes encoding therapeutic proteins for their well-documented function of boosting expression. However, mis-splicing of introns in recombinant immunoglobulin (IgG) heavy chain (HC) transcripts can produce amino acid sequence product variants. These variants can affect product quality; therefore, purification process optimization may be needed to remove them, or if they cannot be removed, then in-depth characterization must be carried out to understand their effects on biological activity. In this study, HC transgene engineering approaches were investigated and were successful in significantly reducing the previously identified IgG HC splice variants to <0.5%. Subsequently, a comprehensive evaluation was conducted to understand the influence of the different introns in the HC genes on the expression of recombinant biotherapeutic antibodies. The data revealed an unexpected cooperation between specific introns for efficient splicing, where intron retention led to significant reductions in IgG expression of up to 75% for some intron combinations. Furthermore, it was shown that HC introns could be fully removed without significantly affecting productivity. This work paves the way for future biotherapeutic antibody transgene design with regard to inclusion of HC introns. By removing unnecessary introns, transgene mRNA transcript will no longer be mis-spliced, thereby eliminating HC splice variants and improving antibody product quality.
Collapse
Affiliation(s)
- Emma Kelsall
- Cell Culture and Fermentation Sciences, Biopharmaceutical Development, R&D, AstraZeneca, Cambridge, UK
| | - Claire Harris
- Cell Culture and Fermentation Sciences, Biopharmaceutical Development, R&D, AstraZeneca, Cambridge, UK
| | - Titash Sen
- Cell Culture and Fermentation Sciences, Biopharmaceutical Development, R&D, AstraZeneca, Cambridge, UK
| | - Diane Hatton
- Cell Culture and Fermentation Sciences, Biopharmaceutical Development, R&D, AstraZeneca, Cambridge, UK
| | - Sarah Dunn
- Cell Culture and Fermentation Sciences, Biopharmaceutical Development, R&D, AstraZeneca, Cambridge, UK
| | - Suzanne Gibson
- Cell Culture and Fermentation Sciences, Biopharmaceutical Development, R&D, AstraZeneca, Cambridge, UK
| |
Collapse
|
4
|
Monoclonal Antibody Sequence Variants Disguised as Fragments: Identification, Characterization, and Their Removal by Purification Process Optimization. J Pharm Sci 2022; 111:3009-3016. [PMID: 35940243 DOI: 10.1016/j.xphs.2022.08.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2022] [Revised: 08/02/2022] [Accepted: 08/02/2022] [Indexed: 12/14/2022]
Abstract
During early stage development of a therapeutic IgG1 monoclonal antibody, high levels of low molecular weight (LMW) peaks were observed by high performance size-exclusion chromatography and capillary electrophoresis. Further characterization of the LMW peak enriched HPSEC fractions using reversed phase liquid chromatography coupled to mass spectrometry showed these LMW species were 47 kDa and 50 kDa in size. However, the measured masses could not be matched to any fragments resulting from peptide bond hydrolysis. To identify these unknown LMW species, molecular characterization methods were employed, including high-throughput sequencing of RNA. Transcriptomic analysis revealed the LMW species were generated by mis-splicing events in the heavy chain transcript, which produced truncated heavy chain products that assembled with the light chain to mimic the appearance of fragments identified by routine purity assays. In an effort to improve product quality, an optimized purification process was developed. Characterization of the process intermediates confirmed removal of both LMW species by the optimized process. Our study demonstrates that deep-dive analytical characterization of biotherapeutics is critical to ensure product quality and inform process development. Transcriptomic analysis tools can help identify the cause of unknown species, and plays a key role in product and process characterization.
Collapse
|
5
|
Lin J, Xie M, Liu D, Gao Z, Zhao X, Ma H, Ding S, Li SM, Li S, Liu Y, Zhou F, Hu H, Chen T, Chen H, Xie M, Yang B, Cheng J, Ma M, Nan Y, Ju D. Characterization of light chain c-terminal extension sequence variant in one bispecific antibody. Front Chem 2022; 10:994472. [PMID: 36204149 PMCID: PMC9530627 DOI: 10.3389/fchem.2022.994472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2022] [Accepted: 09/01/2022] [Indexed: 11/17/2022] Open
Abstract
Protein modifications such as post-translational modifications (PTMs) and sequence variants (SVs) occur frequently during protein biosynthesis and have received great attention by biopharma industry and regulatory agencies. In this study, an aberrant peak near light chain (LC) was observed in the non-reduced capillary electrophoresis sodium dodecyl sulfate (nrCE-SDS) electrophoretogram during cell line development of one bispecific antibody (BsAb) product, and the detected mass was about 944 Da higher than LC. The corresponding peak was then enriched by denaturing size-exclusion chromatography (SEC-HPLC) and further characterized by nrCE-SDS and peptide mapping analyses. De novo mass spectra/mass spectra (MS/MS) analysis revealed that the aberrant peak was LC related sequence variant, with the truncated C-terminal sequence “SFNR” (“GEC”deleted) linked with downstream SV40 promotor sequence “EAEAASASELFQ”. The unusual sequence was further confirmed by comparing with the direct synthetic peptide “SFNREAEAASASELFQ”. It was demonstrated by mRNA sequencing of the cell pool that the sequence variant was caused by aberrant splicing at the transcription step. The prepared product containing this extension variant maintained well-folded structure and good functional properties though the LC/Heavy chain (HC) inter-chain disulfide was not formed. Several control strategies to mitigate the risk of this LC related sequence variant were also proposed.
Collapse
Affiliation(s)
- Jun Lin
- Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, Fudan University School of Pharmacy, Shanghai, China
- Genor Biopharma Co., Ltd., Shanghai, China
| | - Mengyu Xie
- Genor Biopharma Co., Ltd., Shanghai, China
| | - Dan Liu
- Genor Biopharma Co., Ltd., Shanghai, China
| | - Zhen Gao
- Genor Biopharma Co., Ltd., Shanghai, China
| | | | - Hongxia Ma
- Genor Biopharma Co., Ltd., Shanghai, China
| | - Sheng Ding
- Genor Biopharma Co., Ltd., Shanghai, China
| | - Shu mei Li
- Genor Biopharma Co., Ltd., Shanghai, China
| | - Song Li
- Genor Biopharma Co., Ltd., Shanghai, China
| | | | - Fang Zhou
- Genor Biopharma Co., Ltd., Shanghai, China
| | - Hao Hu
- Genor Biopharma Co., Ltd., Shanghai, China
| | - Tao Chen
- Genor Biopharma Co., Ltd., Shanghai, China
| | - He Chen
- Genor Biopharma Co., Ltd., Shanghai, China
| | - Min Xie
- Genor Biopharma Co., Ltd., Shanghai, China
| | - Bo Yang
- Genor Biopharma Co., Ltd., Shanghai, China
| | - Jun Cheng
- Genor Biopharma Co., Ltd., Shanghai, China
| | - Mingjun Ma
- Genor Biopharma Co., Ltd., Shanghai, China
| | - Yanyang Nan
- Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, Fudan University School of Pharmacy, Shanghai, China
| | - Dianwen Ju
- Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, Fudan University School of Pharmacy, Shanghai, China
- *Correspondence: Dianwen Ju,
| |
Collapse
|
6
|
Bosley A, Cook K, Lin S, Robbins D. Improved process intermediate stability through the identification and elimination of reactive glycation residues - a monoclonal antibody case study. Bioengineered 2022; 13:14402-14412. [PMID: 35757891 PMCID: PMC9342189 DOI: 10.1080/21655979.2022.2086350] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
The manufacturing of therapeutic biologics can result in a heterogeneous population of charge variants, encompassing many quality attributes which could impact activity and pharmacokinetics. Monitoring the relative abundance of these charge variants to demonstrate process consistency is an expectation of regulatory agencies. Control of the relative abundance of charge variants is also necessary to ensure product comparability across the product lifecycle. We have observed a significant shift in the relative abundance of charged species, as measured by capillary isoelectric focusing, during clarified cell culture fluid holds for several monoclonal antibodies. This lack of stability requires that the hold time for this process intermediate be significantly curtailed, eliminating manufacturing flexibility. We have identified the cause of this shift in relative abundance of charged species as changes in glycation levels, focused predominantly on three conserved, solvent accessible, lysine residues. Mutants of a model protein were generated that show increased charge state stability can be gained by eliminating these reactive lysines. Further, characterization studies were conducted on these mutants to determine the impact to biological activity and stability of the molecule, with no detrimental effects observed. Incorporating this knowledge into the assessments of candidate drugs could allow for the selection of molecules less susceptible to this product degradation pathway, allowing for greater manufacturing flexibility. This process of identifying and removing reactive lysine residues could be useful in the design of drug candidates with improved charge state stability, across a range of modalities.
Collapse
Affiliation(s)
- Allen Bosley
- Purification Process Sciences, AstraZeneca, Gaithersburg, Maryland, USA
| | - Kimberly Cook
- Antibody Discovery & Protein Engineering, AstraZeneca, Gaithersburg, Maryland, USA
| | - Shihua Lin
- Analytical Biotechnology, AstraZeneca, Gaithersburg, Maryland, USA
| | - David Robbins
- Purification Process Sciences, AstraZeneca, Gaithersburg, Maryland, USA
| |
Collapse
|
7
|
Identification, characterization and control of a sequence variant in monoclonal antibody drug product: a case study. Sci Rep 2021; 11:13233. [PMID: 34168178 PMCID: PMC8225904 DOI: 10.1038/s41598-021-92338-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2020] [Accepted: 02/22/2021] [Indexed: 02/06/2023] Open
Abstract
Sequence variants (SV) in protein bio therapeutics can be categorized as unwanted impurities and may raise serious concerns in efficacy and safety of the product. Early detection of specific sequence modifications, that can result in altered physicochemical and or biological properties, is therefore desirable in product manufacturing. Because of their low abundance, and finite resolving power of conventional analytical techniques, they are often overlooked in early drug development. Here, we present a case study where trace amount of a sequence variant is identified in a monoclonal antibody (mAb) based therapeutic protein by LC-MS/MS and the structural and functional features of the SV containing mAb is assessed using appropriate analytical techniques. Further, a very sensitive selected reaction monitoring (SRM) technique is developed to quantify the SV which revealed both prominent and inconspicuous nature of the variant in process chromatography. We present the extensive characterization of a sequence variant in protein biopharmaceutical and first report on control of sequence variants to < 0.05% in final drug product by utilizing SRM based mass spectrometry method during the purification steps.
Collapse
|
8
|
Grassi L, Harris C, Zhu J, Hardman C, Hatton D. DetectIS: a pipeline to rapidly detect exogenous DNA integration sites using DNA or RNA paired-end sequencing data. Bioinformatics 2021; 37:4230-4232. [PMID: 33978747 PMCID: PMC9502153 DOI: 10.1093/bioinformatics/btab366] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2020] [Revised: 05/07/2021] [Accepted: 05/11/2021] [Indexed: 11/13/2022] Open
Abstract
Motivation Recombinant DNA technology is widely used for different applications in biology, medicine and bio-technology. Viral transduction and plasmid transfection are among the most frequently used techniques to generate recombinant cell lines. Many of these methods result in the random integration of the plasmid into the host genome. Rapid identification of the integration sites is highly desirable in order to characterize these engineered cell lines. Results We developed detectIS: a pipeline specifically designed to identify genomic integration sites of exogenous DNA, either a plasmid containing one or more transgenes or a virus. The pipeline is based on a Nextflow workflow combined with a Singularity image containing all the necessary software, ensuring high reproducibility and scalability of the analysis. We tested it on simulated datasets and RNA-seq data from a human sample infected with Hepatitis B virus. Comparisons with other state of the art tools show that our method can identify the integration site in different recombinant cell lines, with accurate results, lower computational demand and shorter execution times. Availability and implementation The Nextflow workflow, the Singularity image and a test dataset are available at https://github.com/AstraZeneca/detectIS. Supplementary information Supplementary data are available at Bioinformatics online.
Collapse
Affiliation(s)
- Luigi Grassi
- Biopharmaceutical Development, BioPharmaceuticals R&D, AstraZenec, Cambridge, UK a
| | - Claire Harris
- Biopharmaceutical Development, BioPharmaceuticals R&D, AstraZenec, Cambridge, UK a
| | - Jie Zhu
- Biopharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, USA
| | - Colin Hardman
- Data Science & Artificial Intelligence, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
| | - Diane Hatton
- Biopharmaceutical Development, BioPharmaceuticals R&D, AstraZenec, Cambridge, UK a
| |
Collapse
|